GlassScriptPhysician profile
Melissa A Hodge
NPI 1962600379
$6,070.48
in general payments reported to CMS, 2019-2025
30 companies · $931 in 2025
The $931 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $335 · 2021: $1,035 · 2022: $1,068 · 2023: $958 · 2024: $1,019 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.66 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.53 | 2019-2024 | |
| Hologic Sales and Service, LLC | $904.19 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Astellas Pharma US INC | $622.26 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $463.37 | 2021-2025 | |
| Pfizer INC. | $433.20 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.81 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $248.12 | 2023-2025 | Myfembree |
| Biogen, INC. | $228.01 | 2024-2025 | Zurzuvae |
| Medtronic, INC. | $210.03 | 2022-2024 | Truclear |
| Therapeuticsmd, INC. | $186.52 | 2019-2021 | |
| Coopersurgical, INC. | $164.87 | 2019-2021 | |
| Daiichi Sankyo INC. | $153.41 | 2021-2022 | |
| Myovant Sciences INC. | $146.79 | 2021-2022 | |
| Exeltis, USA INC. | $102.96 | 2020-2025 | Slynd |
| Agile Therapeutics, INC. | $92.43 | 2021-2024 | Twirla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $73.66 | 2020-2021 | |
| Duchesnay USA Incorporated | $46.19 | 2019 | |
| Allergan, INC. | $45.85 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $41.74 | 2021 | |
| Smith+Nephew, INC. | $35.55 | 2020-2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Shield Therapeutics INC | $30.36 | 2025 | |
| Dexcom, INC. | $24.46 | 2025 | Dexcom G6 Transmitter |
| Myriad Genetic Laboratories, INC. | $22.22 | 2024 | Myrisk |
| Merck Sharp & Dohme LLC | $20.39 | 2024 | Gardasil 9, Gardasil |
| Heron Therapeutics, INC. | $18.01 | 2022 | |
| Northgate Technologies, INC. | $16.82 | 2024 | Stimsite |
| Scynexis, INC. | $16.37 | 2022 | |
| Exact Sciences Corporation | $15.63 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $14.38 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.